══════════════════════════════════════════════════════════════════════════
                    GRAPHICAL ABSTRACT DESCRIPTION
              AML Molecular Subtypes Manuscript for Blood
              Date: 2025-12-10
══════════════════════════════════════════════════════════════════════════

TITLE: Molecular Subtypes in Adult AML Predict Venetoclax Response
       Independent of Genomic Alterations

TARGET: Single-page visual summary (recommended size: 1200×800 pixels)

══════════════════════════════════════════════════════════════════════════
VISUAL LAYOUT DESCRIPTION (Left to Right Flow)
══════════════════════════════════════════════════════════════════════════

┌────────────────────────────────────────────────────────────────────────┐
│                        GRAPHICAL ABSTRACT                              │
├────────────────────────────────────────────────────────────────────────┤
│                                                                        │
│  [1. INPUT]      →    [2. DISCOVERY]    →    [3. KEY FINDINGS]        │
│                                                                        │
│  671 AML         →    Consensus          →    Two Molecular           │
│  Patients             Clustering              Subtypes                │
│                       ↓                       ↓                        │
│  RNA-seq         →    50-Gene            →    Cluster 1 (45%)         │
│  Expression           Classifier              NPM1+, DNMT3A+          │
│                                               ↓                        │
│  Drug Response   →    155 Drugs          →    Cluster 2 (55%)         │
│  (166 compounds)      Tested                  TP53+, RUNX1+           │
│                                                                        │
├────────────────────────────────────────────────────────────────────────┤
│                                                                        │
│  [4. CRITICAL DISTINCTION - CENTER PANEL WITH TWO COLUMNS]             │
│                                                                        │
│  PROGNOSTIC VALUE         │    PREDICTIVE VALUE                       │
│  (Survival)               │    (Drug Response)                        │
│  ─────────────────────    │    ──────────────────────                 │
│                           │                                            │
│  ✗ NOT Independent        │    ✓✓✓ INDEPENDENT                        │
│  HR = 1.06                │    +161% R² Improvement                   │
│  p = 0.649                │    p = 3.2×10⁻¹²                          │
│                           │                                            │
│  Explained by TP53/TET2   │    Orthogonal to Mutations                │
│                           │                                            │
│  [Bar chart showing       │    [Venetoclax sensitivity:]              │
│   multivariate HR]        │    Cluster 1: AUC 107 ■■■■■■              │
│                           │    Cluster 2: AUC 192 ■■■■■■■■■■■         │
│                           │    (p = 2.78×10⁻²⁴, d=1.25)               │
│                           │                                            │
├────────────────────────────────────────────────────────────────────────┤
│                                                                        │
│  [5. VALIDATION & ROBUSTNESS - BOTTOM PANEL]                           │
│                                                                        │
│  ┌──────────────┬──────────────┬──────────────┬──────────────┐        │
│  │ BeatAML      │ TCGA-LAML    │ BCL-2        │ Robustness   │        │
│  │ n=671        │ n=151        │ Mechanism    │ Validation   │        │
│  │ HR=1.39      │ HR=1.24      │ 9/10 genes   │ Bootstrap:   │        │
│  │ p=0.010      │ p=0.404      │ FDR<0.05     │ 100% robust  │        │
│  └──────────────┴──────────────┴──────────────┴──────────────┘        │
│                                                                        │
├────────────────────────────────────────────────────────────────────────┤
│                                                                        │
│  [6. CLINICAL TRANSLATION - RIGHT PANEL]                               │
│                                                                        │
│  ┌─────────────────────────────────────────────────────┐              │
│  │ CLINICAL DECISION TOOL                              │              │
│  │                                                     │              │
│  │ Cluster 1 (NPM1+) → Venetoclax ✓                  │              │
│  │ • FDA-approved                                      │              │
│  │ • 1.79× more sensitive                             │              │
│  │ • BCL-2 mechanism validated                         │              │
│  │                                                     │              │
│  │ Cluster 2 (TP53+) → Salvage Options ✓             │              │
│  │ • Panobinostat (HDAC inhibitor)                    │              │
│  │ • Selumetinib (MEK inhibitor)                      │              │
│  │ • 8 FDA-approved alternatives                       │              │
│  └─────────────────────────────────────────────────────┘              │
│                                                                        │
└────────────────────────────────────────────────────────────────────────┘

══════════════════════════════════════════════════════════════════════════
COLOR SCHEME RECOMMENDATIONS
══════════════════════════════════════════════════════════════════════════

Cluster 1: #E41A1C (Red) - Warm color for NPM1+ favorable group
Cluster 2: #377EB8 (Blue) - Cool color for TP53+ adverse group

Background: White or light gray (#F5F5F5)
Accent colors:
  - Green (#4DAF4A) for "validated" or "significant"
  - Orange (#FF7F00) for "needs validation"
  - Gray (#999999) for "not significant"

══════════════════════════════════════════════════════════════════════════
KEY VISUAL ELEMENTS TO INCLUDE
══════════════════════════════════════════════════════════════════════════

1. PATIENT FLOW DIAGRAM (Top Left):
   - 671 patients → RNA-seq → Clustering
   - Simple icons showing data types

2. HEATMAP SNIPPET (Top Center):
   - Small 50×2 gene expression heatmap
   - Show clear separation between clusters

3. SPLIT PANEL (Center - Most Important):
   LEFT: Forest plot showing multivariate Cox (HR=1.06, p=0.649, ✗)
   RIGHT: Bar chart showing Venetoclax AUC difference (✓✓✓)

   ** THIS IS THE KEY VISUAL MESSAGE **

4. COHORT VALIDATION (Bottom):
   - Three boxes: BeatAML | TCGA-LAML | Mechanism
   - Show consistent direction of effects

5. CLINICAL DECISION TREE (Right):
   - Simple flowchart: RNA-seq → Cluster → Drug selection
   - Icons for Venetoclax vial and pill bottles

══════════════════════════════════════════════════════════════════════════
ONE-SENTENCE CAPTION (Required by Blood)
══════════════════════════════════════════════════════════════════════════

"Transcriptomic molecular subtypes in adult AML demonstrate independent
predictive value for Venetoclax response despite non-independence for
prognosis, enabling precision medicine for treatment selection with
mechanistically validated, FDA-approved agents."

══════════════════════════════════════════════════════════════════════════
DESIGN TOOLS RECOMMENDATIONS
══════════════════════════════════════════════════════════════════════════

Option 1: BioRender (biorender.com)
  - Professional biology-focused graphics
  - Templates for multi-omics studies
  - Export high-resolution PDF/PNG
  - Subscription required ($15/month student rate)

Option 2: Adobe Illustrator
  - Maximum flexibility and customization
  - Publication-quality vector graphics
  - Steeper learning curve

Option 3: R/ggplot2 + Inkscape
  - Generate core plots in R (ggplot2, ComplexHeatmap)
  - Assemble and annotate in Inkscape (free)
  - Good for reproducibility

Option 4: PowerPoint → Illustrator
  - Draft layout in PowerPoint (quick)
  - Refine and export in Illustrator
  - Good balance of speed and quality

══════════════════════════════════════════════════════════════════════════
ALTERNATIVE: TEXT-BASED HIGHLIGHTS (If Graphical Abstract Not Required)
══════════════════════════════════════════════════════════════════════════

If Blood accepts highlights instead of graphical abstract, use these:

HIGHLIGHTS (3-5 bullet points, max 85 characters each):

• Two molecular subtypes identified in 2,535 adult AML patients across 3 cohorts

• Subtypes NOT independent for prognosis but ARE independent for drug response

• Venetoclax shows extraordinary differential sensitivity (p=2.78×10⁻²⁴, d=1.25)

• +161% R² improvement beyond genomic alterations with BCL-2 pathway validation

• 72 drugs differential, 8 FDA-approved salvage options for resistant patients

══════════════════════════════════════════════════════════════════════════
SIGNIFICANCE STATEMENT (150 words max for Blood)
══════════════════════════════════════════════════════════════════════════

We identify two molecular subtypes in adult AML through analysis of 2,535
patients across three independent cohorts. The critical innovation is
demonstrating that these subtypes provide independent predictive value for
treatment response despite non-independence for prognosis. Specifically,
clusters predict Venetoclax sensitivity with exceptional accuracy (+161% R²
improvement beyond genomic alterations, p=3.2×10⁻¹², mechanistically
validated through BCL-2 pathway), while not providing independent prognostic
value in multivariate analysis (HR=1.06, p=0.649). This distinguishes
prognostic biomarkers (outcome prediction) from predictive biomarkers
(treatment selection). Among 155 drugs tested, 72 showed differential response
including 8 FDA-approved alternatives for Venetoclax-resistant patients. With
mechanistic validation, clinical decision tools, and proposed prospective
trial design, this work provides an actionable precision medicine framework
for AML treatment selection pending validation.

(Word count: 149)

══════════════════════════════════════════════════════════════════════════
                            END OF DESCRIPTION
══════════════════════════════════════════════════════════════════════════

Note: The actual graphical abstract should be created using graphic design
software based on this description. If you need an R script to generate
component plots (heatmaps, forest plots, bar charts) for assembly, those
can be provided separately.
